EUVIMEDOpdag EUVIMED
Crossref

Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma

Shuo Li, Zhixiong Wang, Meiling Zhou iD, Weilu Jia, Zonghan Shi, XinYu Mao, Weijie Zhao, Boyu Xia, Zhe Wang, Xinhao Li, YeWei Zhang iD

ACS Applied Materials & Interfaces · 2026

DOI: 10.1021/acsami.6c02880 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2026. Written by Shuo Li and 10 co-authors. Institution: Nanjing Medical University, Nanjing 210009, China. Major MEDLINE topics: Liposomes, Ferroptosis, Carcinoma, Hepatocellular, Liver Neoplasms. Cited 3 times so far (Crossref); 28 references. Funded by: Natural Science Foundation of Jiangsu Province, National Major Scientific Research Instrument Development Project, National Natural Science Foundation of China (NSFC).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hepatocellular carcinoma (HCC), a highly prevalent malignancy, is mostly diagnosed at intermediate and advanced stages. Current monotherapies are limited by poor targeting, severe toxicity, drug resistance, and high metastatic risk, necessitating more effective precision therapeutic strategies. Photothermal therapy (PTT) and ferroptosis induction are promising for HCC treatment, but violet phosphorus nanoparticles (VPNs) alone confer limited PTT efficacy, while the ferroptosis inducers RSL3 and sulfasalazine (SSZ) are hampered by poor aqueous solubility, low biostability, and off-target toxicity, restricting their clinical translation. Herein, we constructed a glypican-3 (GPC3)-targeted multifunctional nanodelivery system for synergistic PTT-ferroptosis anti-HCC therapy. Liposomes coloading RSL3, SSZ and encapsulating VPNs (VRS@LP) were first synthesized. Macrophage membranes engineered to express the GPC3-specific single-chain antibody hGPC3 (M-hGPC3) were prepared via lentiviral transduction, then coated onto VRS@LP by mechanical extrusion to yield the targeted nanocarrier VRS@MLP-hGPC3.This nanocarrier achieves receptor-mediated endocytosis via specific hGPC3-GPC3 binding on HCC cells, with drug release triggered by the acidic lysosomal microenvironment. RSL3 inhibits glutathione peroxidase 4 (GPX4) activity, and SSZ blocks System xc--mediated cystine uptake; their combination synergistically depletes intracellular glutathione (GSH) and potently induces ferroptosis in HCC cells. The nanoplatform-mediated PTT not only directly ablates tumor cells but also releases damage-associated molecular patterns (DAMPs), promoting dendritic cell maturation, T-cell activation, and tumor-associated macrophage polarization. Meanwhile, PTT-generated reactive oxygen species (ROS) synergize with ferroptosis to amplify oxidative injury and reduce HCC metastatic potential. The GPC3-targeted nanodelivery system enables precise synergistic PTT-ferroptosis therapy with high targeting efficiency, favorable biocompatibility and low systemic toxicity, significantly enhancing HCC therapeutic efficacy and suppressing metastasis. This work provides a potential strategy and experimental basis for precision HCC therapy, with promising clinical translational potential.

Subjects

MeSH terms (MEDLINE)

LiposomesFerroptosisCarcinoma, HepatocellularLiver NeoplasmsNanoparticlesPhosphorusHumansAnimalsGlypicansImmunotherapyCell Line, TumorPhotothermal TherapyMiceGenetic Engineering

Author keywords

cancer immunotherapyferroptosisgenetically engineered membranephotodynamic therapyviolet phosphorus

Substances

LiposomesGlypicansPhosphorus

Authors and institutions

  • Nanjing Medical University, Nanjing 210009, China.
  • Department of Pharmacy, Zhongda Hospital, School of Medicine, Southeast University, Nanjing 210009, Jiangsu, China.
  • Department of Hepatobiliary Surgery, Zhongda Hospital, Southeast University, Nanjing 210009, China.
  • Hepatopancreatobiliary Center, The Second Affiliated Hospital of Nanjing Medical University, Nanjing 210009, China.

ORCID profiles: Meiling Zhou, YeWei Zhang

Funding

  • Natural Science Foundation of Jiangsu Province
  • National Major Scientific Research Instrument Development Project
  • National Natural Science Foundation of China (NSFC)

Cite

APA

Li, S., Wang, Z., Zhou, M., Jia, W., Shi, Z., Mao, X., Zhao, W., Xia, B., Wang, Z., Li, X., & Zhang, Y. (2026). Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c02880

Vancouver

Li S, Wang Z, Zhou M, Jia W, Shi Z, Mao X, et al. Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c02880

BibTeX
@article{Li2026,
  author = {Li, Shuo and Wang, Zhixiong and Zhou, Meiling and Jia, Weilu and Shi, Zonghan and Mao, XinYu and Zhao, Weijie and Xia, Boyu and Wang, Zhe and Li, Xinhao and Zhang, YeWei},
  title = {Genetically Engineered Membrane-Mimetic Liposome-Wrapped Violet Phosphorus Nanoplatform for Targeted Synergistic Ferroptosis/Photothermal/Immunotherapy of Hepatocellular Carcinoma},
  journal = {ACS Applied Materials & Interfaces},
  year = {2026},
  doi = {10.1021/acsami.6c02880}
}
Start for free →